Target intelligence / Profile preview

Claudin-2 (CLDN2) mRNA (CLDN2 mRNA)

Target
CLDN2 mRNA
Molecular classification
Messenger RNA, Tight junction protein family
01

Overview

Claudin-2 is a pore-forming tight junction protein that facilitates the paracellular movement of water and small cations, primarily sodium, across epithelial layers (UniProt P57730). While it is essential for normal physiological processes in the kidney and intestinal crypts, its pathologically high expression in the intestinal villi is a hallmark of Inflammatory Bowel Disease (IBD), including Ulcerative Colitis and Crohn's disease (PubMed: 28453519). This overexpression leads to increased intestinal permeability, often referred to as 'leaky gut,' which exacerbates inflammation and causes diarrhea (PubMed: 31433954). Targeting the Claudin-2 mRNA allows for the downregulation of this protein at the pre-translational level, offering a novel approach to restoring intestinal barrier integrity. Current therapeutic candidates, such as the antisense oligonucleotide ION-829, are designed to bind specifically to the CLDN2 transcript and trigger its degradation (Ionis Pharmaceuticals, 2023). However, because Claudin-2 also plays a role in renal ion reabsorption in the proximal tubule, safety monitoring for electrolyte disturbances is a critical component of clinical development (PubMed: 24737868). By reducing the abundance of Claudin-2 protein, these therapies aim to decrease the paracellular leak of ions and water into the intestinal lumen, thereby alleviating symptoms and promoting mucosal healing.

Other names
CLDN2 mRNAClaudin-2 transcriptMessenger RNA encoding Claudin-2
02

Mechanism of action

Antisense oligonucleotide-mediated degradation of mRNA via RNase H, leading to reduced translation of the Claudin-2 protein.

03

Biological functions

Paracellular cation transportWater transportTight junction assemblyIon homeostasis
04

Disease associations

Inflammatory Bowel DiseaseUlcerative ColitisCrohn's DiseaseColorectal CancerDiarrhea
05

Safety considerations

Potential renal electrolyte imbalanceGallbladder dysfunctionOff-target effects on other claudin family members
06

Interacting drugs

ION-829
07

Biomarkers

CLDN2 mRNA expression levelsFecal calprotectinIntestinal paracellular permeability

Beyond the preview

Go deeper on Claudin-2 (CLDN2) mRNA (CLDN2 mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Claudin-2 (CLDN2) mRNA (CLDN2 mRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call